KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Assets: 2019-2024

Historic Assets for Royalty Pharma (RPRX) over the last 6 years, with Dec 2024 value amounting to $18.2 billion.

  • Royalty Pharma's Assets rose 7.23% to $19.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $19.3 billion, marking a year-over-year increase of 7.23%. This contributed to the annual value of $18.2 billion for FY2024, which is 11.24% up from last year.
  • As of FY2024, Royalty Pharma's Assets stood at $18.2 billion, which was up 11.24% from $16.4 billion recorded in FY2023.
  • In the past 5 years, Royalty Pharma's Assets registered a high of $18.2 billion during FY2024, and its lowest value of $16.0 billion during FY2020.
  • For the 3-year period, Royalty Pharma's Assets averaged around $17.1 billion, with its median value being $16.8 billion (2022).
  • As far as peak fluctuations go, Royalty Pharma's Assets climbed by 28.68% in 2020, and later fell by 4.01% in 2022.
  • Royalty Pharma's Assets (Yearly) stood at $16.0 billion in 2020, then rose by 9.34% to $17.5 billion in 2021, then declined by 4.01% to $16.8 billion in 2022, then decreased by 2.57% to $16.4 billion in 2023, then increased by 11.24% to $18.2 billion in 2024.